| Website | glaukos.com |
| Phone | 949-367-9600 |
| Employees |
| Total | $64.5M |
| Series D, 8/08 OrbiMed Advisors Frazier Healthcare Ventures InterWest Partners Domain Associates Fjord Ventures Montreux Equity Partners Versant Ventures | $35M |
| Series E, 2/11 | $29.5M |
Glaukos Corporation is committed to transforming glaucoma therapy. To this end, Glaukos is bypassing anatomical impediments and treatment conventions to develop treatments that restore natural physiologic outflow as a foundation of significant, steady and sustained glaucoma management. Today, they are at the beginning with an innovative micro technology. In collaboration with their clinician partners, they are building technology towards a safer and more effective treatment for preserving vision in patients with primary open-angle glaucoma.
